http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
-
Vertex Pharma (VRTX) Reports Positive CHMP Opinion for CASGEVY
-
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thal
-
Vertex Pharma (VRTX) Reports Positive Results From Phase 2 Study of VX-548
-
Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
-
Vertex Pharma (VRTX) Presents Positive Results from Pivotal Trials of CASGEVY
-
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
-
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™
-
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
-
Vertex Pharma (VRTX) Appoints Nancy Thornberry to its Board of Directors
-
Vertex Appoints Nancy Thornberry to its Board of Directors
-
Vertex Pharma (VRTX) Announces EMA Validation for Marketing Authorization Application Extension for KAFTRIO in Combination With Ivacaftor
-
Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO® in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsiv
-
Vertex Pharma (VRTX) Announces EU Approval of KAFTRIO in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
-
European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
-
Vertex Pharma (VRTX) and CRISPR Therapeutics (CRSP) Announce Authorization of the CASGEVY in the UK
-
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell
-
Vertex Reports Third Quarter 2023 Financial Results
-
Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition
-
Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference
-
Vertex to Present at Upcoming Investor Conferences
-
Vortex Energy Announces Extension of Marketing Program
-
Vertex to Announce Third Quarter 2023 Financial Results on November 6
-
Vertex Pharma (VRTX) Appoints Michel Lagarde to its Board
-
Vertex Appoints Michel Lagarde to its Board of Directors
-
Vertex Pharma (VRTX) Presents Positive, Updated VX-880 Results
-
Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting
-
Vertex Pharma (VRTX) Receives CHMP Positive Opinion for KAFTRIO in Combination With Ivacaftor
-
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
-
Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
-
Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13
-
Vertex Pharma (VRTX) Appoints E. Morrey Atkinson as EVP and Chief Technical Operations Officer
-
Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations
-
Vertex Pharma (VRTX) Reports Publication of VX-548 Positive Phase 2,
-
Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine
-
Vertex Reports Second Quarter 2023 Financial Results
-
Vertex Pharma (VRTX) Announces Approval of ORKAMBI in EU
-
European Commission Approves ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old
-
Vertex to Announce Second Quarter 2023 Financial Results on August 1
-
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
-
Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
-
Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
-
Vertex Pharma (VRTX) Announces FDA Acceptance of BLA for exagamglogene autotemcel for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
-
Vertex Pharma (VRTX) Reports Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease
-
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
-
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
-
Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
-
Vertex Pharma (VRTX) Announces FDA Approval of KALYDECO
-
Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
-
Vertex Reports First Quarter 2023 Financial Results
